Suppr超能文献

Th22 细胞和 Th17 细胞在骨髓增生异常综合征早期和晚期患者中呈差异化扩增。

Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.

机构信息

Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.

出版信息

PLoS One. 2012;7(12):e51339. doi: 10.1371/journal.pone.0051339. Epub 2012 Dec 7.

Abstract

BACKGROUND

Immunological mechanisms are increasingly recognized in the progression of myelodysplastic syndrome (MDS). Early-stage MDS (E-MDS) is characterized by autoimmune-mediated myelosuppression whereas late-stage MDS (L-MDS) involves immune evasion, giving dysplastic cells growth potential to progress into acute myeloid leukemia. T-helper (Th) 22 is involved in the pathogenesis of inflammatory autoimmunity and tumorigenesis. The roles of Th22 cells in the pathophysiology of E-MDS and L-MDS remain unsettled.

DESIGN AND METHODS

We studied 37 MDS patients (E-MDS, n = 17; L-MDS, n = 20) and 20 healthy controls to characterize their peripheral blood (PB), as well as 25 MDS patients and 10 healthy controls to characterize their bone marrow(BM). The expression of Interleukin-22 (IL-22), IL-17 or interferon gamma (IFN-γ) was examined in E-MDS, L-MDS patients and controls by flow cytometry. The mRNA expression levels of RAR-related orphan receptor C (RORC), IL-6, tumor necrosis factor alpha (TNF-α) and IL-23 in peripheral blood mononuclear cells (PBMCs) were determined by real-time quantitative polymerase chain reaction. The levels of IL-22 and IL-17 both in PB and BM plasma were examined by enzyme-linked immunosorbent assay.

RESULTS

In E-MDS, peripheral Th17 cells were significantly elevated and correlated with peripheral Th22 cells compared with healthy controls and L-MDS. Significantly higher levels of peripheral Th22 expansion, mRNA expression of IL-6, TNF-α and lower level of RORC mRNA expression were observed in L-MDS compared with E-MDS. No statistical difference was found in IL-23 mRNA expression or plasma IL-22, IL-17 levels among E-MDS, L-MDS and controls.

CONCLUSIONS

Our data demonstrated that L-MDS cohort had increased frequencies of peripheral Th22 cells and higher mRNA expression levels of IL-6 and TNF-α, indicating that Th22 cells along with Th17 cells or not are involved in the dynamic immune responses of MDS.

摘要

背景

免疫机制在骨髓增生异常综合征(MDS)的进展中越来越受到重视。早期 MDS(E-MDS)的特征是自身免疫介导的骨髓抑制,而晚期 MDS(L-MDS)则涉及免疫逃逸,使病态细胞获得生长潜能,进展为急性髓系白血病。辅助性 T 细胞 22(Th22)参与炎症性自身免疫和肿瘤发生的发病机制。Th22 细胞在 E-MDS 和 L-MDS 病理生理学中的作用仍未确定。

设计与方法

我们研究了 37 名 MDS 患者(E-MDS,n = 17;L-MDS,n = 20)和 20 名健康对照者的外周血(PB),以及 25 名 MDS 患者和 10 名健康对照者的骨髓(BM)。通过流式细胞术检测 E-MDS、L-MDS 患者和对照组的白细胞介素 22(IL-22)、IL-17 或干扰素 γ(IFN-γ)的表达。实时定量聚合酶链反应测定外周血单个核细胞(PBMCs)中 RAR 相关孤儿受体 C(RORC)、IL-6、肿瘤坏死因子 α(TNF-α)和 IL-23 的 mRNA 表达水平。通过酶联免疫吸附试验检测 PB 和 BM 血浆中 IL-22 和 IL-17 的水平。

结果

与健康对照者和 L-MDS 相比,E-MDS 患者外周血 Th17 细胞明显升高,并与外周血 Th22 细胞相关。与 E-MDS 相比,L-MDS 患者外周血 Th22 细胞扩增、IL-6、TNF-αmRNA 表达水平显著升高,RORC mRNA 表达水平较低。E-MDS、L-MDS 和对照组之间,IL-23 mRNA 表达或血浆 IL-22、IL-17 水平无统计学差异。

结论

我们的数据表明,L-MDS 组外周血 Th22 细胞频率增加,IL-6 和 TNF-αmRNA 表达水平升高,提示 Th22 细胞与 Th17 细胞一起或不一起参与 MDS 的动态免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48a0/3517399/dea5062f9d7f/pone.0051339.g001.jpg

相似文献

3
[The clinical significance of Th17 cells in patients with myelodysplastic syndrome and iron overload].
Zhonghua Nei Ke Za Zhi. 2019 Jun 1;58(6):419-422. doi: 10.3760/cma.j.issn.0578-1426.2019.06.004.
6
Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia.
Hum Immunol. 2012 Jun;73(6):629-35. doi: 10.1016/j.humimm.2012.04.015. Epub 2012 Apr 23.
7
[The Role of Notch Signaling Pathway in Adult Patients with Epstein-Barr Virus-induced Infectious Mononucleosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):920-926. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.041.
9
The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.
J Immunol Res. 2015;2015:416123. doi: 10.1155/2015/416123. Epub 2015 Apr 27.

引用本文的文献

1
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.
Biomolecules. 2025 May 25;15(6):761. doi: 10.3390/biom15060761.
3
Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era.
Front Oncol. 2024 Oct 31;14:1447001. doi: 10.3389/fonc.2024.1447001. eCollection 2024.
4
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May.
5
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Blood Adv. 2023 Jun 13;7(11):2401-2417. doi: 10.1182/bloodadvances.2022008985.
7
The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.
Front Immunol. 2022 Sep 23;13:994053. doi: 10.3389/fimmu.2022.994053. eCollection 2022.
8
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.
Diagnostics (Basel). 2022 Jul 7;12(7):1659. doi: 10.3390/diagnostics12071659.
10
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.
Nat Immunol. 2021 Apr;22(4):520-529. doi: 10.1038/s41590-021-00895-4. Epub 2021 Mar 22.

本文引用的文献

1
Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival.
Cancer Immunol Immunother. 2012 Nov;61(11):1965-75. doi: 10.1007/s00262-012-1241-5. Epub 2012 Apr 13.
2
Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy.
Am J Respir Crit Care Med. 2012 Mar 15;185(6):660-9. doi: 10.1164/rccm.201107-1198OC. Epub 2011 Dec 28.
3
IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes.
Leukemia. 2012 Apr;26(4):693-9. doi: 10.1038/leu.2011.251. Epub 2011 Sep 13.
4
Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis.
J Clin Immunol. 2011 Aug;31(4):606-14. doi: 10.1007/s10875-011-9540-8. Epub 2011 May 10.
5
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Br J Haematol. 2011 Jun;153(5):568-81. doi: 10.1111/j.1365-2141.2011.08683.x. Epub 2011 Apr 13.
6
Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes.
Clin Immunol. 2011 Jun;139(3):350-9. doi: 10.1016/j.clim.2011.03.001. Epub 2011 Mar 8.
10
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
Blood. 2010 Jul 1;115(26):5385-92. doi: 10.1182/blood-2009-10-246660. Epub 2010 Apr 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验